Presence of a growth-stimulating factor in serum following primary tumor removal in mice
- PMID: 2702641
Presence of a growth-stimulating factor in serum following primary tumor removal in mice
Abstract
The effect of removal of a primary tumor on the kinetics of cells in a metastasis was evaluated using six different tumors (C3H, MXTa, MXTb, MC54, CD8, and 3LL) which varied relative to their origin, histology, and the strain of mice in which they were carried. There was an increase in the labeling index (LI) of distant tumor focus ("metastasis") associated with the removal of each of the tumor types and unrelated to operative and anesthetic trauma. Information presented supports the presence of a serum growth factor as being responsible for the phenomenon. Serum obtained from mice following removal of a tumor, when transferred to a recipient with the same type of tumor as in the donor, resulted in an increase in the LI of the tumor. Multiple injections of serum failed to add to the increase but did prolong its presence, suggesting that there is a finite population of cells, most likely in the G1-G0 phase, which are capable of responding to the stimulating factor. The transfer of serum obtained following removal of a tumor type different from that in recipients resulted in findings which indicate that tumors producing a stimulating growth factor are those capable of responding to it. Serum obtained from animals with unremoved tumors or less than 18 h after removal failed to substantially augment the LI of tumors in recipients. It is postulated that the growth factor released by a tumor is in an inactive form which becomes activated over time. Observations indicate that medium conditioned by the growth of C3H tumor contains a growth-stimulating factor which is capable of increasing the LI of a C3H tumor in a recipient in a fashion similar to that obtained following tumor removal. That finding indicates the capability of the tumor to elaborate growth-stimulating material which may be similar to that found in serum. The findings presented refute the premise that removal of a primary tumor is a local phenomenon with no other biological consequences. They indicate that, following primary tumor removal, metastatic behavior may be affected by an interplay of growth factor(s) which can influence the outcome of a host to its tumor.
Similar articles
-
Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice.Cancer Res. 1989 Apr 15;49(8):2002-4. Cancer Res. 1989. PMID: 2522814
-
Effect of surgical removal on the growth and kinetics of residual tumor.Cancer Res. 1979 Oct;39(10):3861-5. Cancer Res. 1979. PMID: 476622
-
Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.Cancer Res. 1983 Apr;43(4):1488-92. Cancer Res. 1983. PMID: 6831397
-
Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity.J Natl Cancer Inst. 1980 Dec;65(6):1257-64. J Natl Cancer Inst. 1980. PMID: 6933271
-
Modeling growth kinetics and statistical distribution of oligometastases.Semin Radiat Oncol. 2006 Apr;16(2):111-9. doi: 10.1016/j.semradonc.2005.12.006. Semin Radiat Oncol. 2006. PMID: 16564446 Review.
Cited by
-
Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition.Brain Behav Immun. 2016 Nov;58:91-98. doi: 10.1016/j.bbi.2016.05.017. Epub 2016 May 25. Brain Behav Immun. 2016. PMID: 27235931 Free PMC article.
-
A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?World J Urol. 2019 Nov;37(11):2343-2353. doi: 10.1007/s00345-019-02652-7. Epub 2019 Jan 31. World J Urol. 2019. PMID: 30706122
-
Prevention of liver metastases through perioperative acute CpG-C immune stimulation.Cancer Immunol Immunother. 2020 Oct;69(10):2021-2031. doi: 10.1007/s00262-020-02596-7. Epub 2020 May 13. Cancer Immunol Immunother. 2020. PMID: 32405793 Free PMC article.
-
Oligometastatic breast cancer: A mini review.Indian J Med Paediatr Oncol. 2014 Jul;35(3):203-6. doi: 10.4103/0971-5851.142035. Indian J Med Paediatr Oncol. 2014. PMID: 25336790 Free PMC article. Review.
-
Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study.J Cancer Res Clin Oncol. 2021 Aug;147(8):2447-2458. doi: 10.1007/s00432-021-03525-6. Epub 2021 Jan 31. J Cancer Res Clin Oncol. 2021. PMID: 33517468 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials